JYJinbao Yang

Jinbao Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinbao Yang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • An Zhu

    Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350108, China

    1 shared publication
  • Guijun Lu

    Endoscopic Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China

    1 shared publication
  • Jiabin Huang

    Department of Pathology & Institute of Oncology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China

    1 shared publication
  • Jing Qi

    Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China

    1 shared publication
  • Lijuan Zhuo

    Department of Pathology & Institute of Oncology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China

    1 shared publication
  • Meiting Zhang

    Department of Pathology & Institute of Oncology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China

    1 shared publication

Latest Publications

  • Open Access

    Eupatorium lindleyanum DC Ameliorates Carbon Tetrachloride-Induced Hepatic Inflammation and Fibrotic Response in Mice

    by Jinbao Yang, Yufei Wang, Lijuan Zhuo, Guijun Lu, Meiting Zhang, Jiabin Huang, Yehaomin Li, Wenwen Liu, Jing Qi, An Zhu, et al.

    Background/Objectives: Eupatorium lindleyanum DC (Eup), a traditional Chinese medicinal herb, is widely used for treating inflammation-mediated diseases, including pneumonia. However, its potential therapeutic effects on inflammation-driven liver fibrosis remain to be elucidated. This study aimed to investigate the effects of Eup on carbon tetrachloride (CCl4)-induced liver fibrosis and elucidate its underlying mechanisms. Methods: The chemical constituents of Eup were analyzed using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF-LC/MS). A CCl4-induced liver fibrosis murine model and LX-2 cells were used in study. Serum biochemical assays, histological analysis, qRT-PCR, ELISA, and Western blot were used to assess Eup’s anti-inflammatory and anti-fibrotic properties. RNA sequencing (RNA-seq) was employed to identify potential mechanisms, with validation by Western blot. Results: 89 and 49 compounds were identified in Eup under positive and negative ion modes, respectively. In vivo, Eup treatment decreased collagen deposition and expression levels of fibrosis-related genes, including collagen I and α-smooth muscle actin. Additionally, Eup alleviated hepatic inflammation. In vitro, Eup inhibited FBS-induced hepatic stellate cell (HSCs) activation. Gene set enrichment analysis (GSEA) indicated that Eup significantly downregulated the platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor-beta (PDGFR-β) signaling pathway, which was further validated in both CCl4-induced fibrotic livers and PDGF-BB-activated HSCs using western blot. Conclusions: Eup attenuated liver fibrosis by inhibiting inflammation and suppressing HSCs activation via downregulating PDGF/PDGFR-β signaling pathway.